Publication:
NAFLD and AATD Are Two Diseases with Unbalanced Lipid Metabolism: Similarities and Differences

dc.contributor.authorPerez-Luz, Sara
dc.contributor.authorMatamala, Nerea
dc.contributor.authorGomez-Mariano, Gema Maria
dc.contributor.authorJanciauskiene, Sabina
dc.contributor.authorMartinez-Delgado, Beatriz
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderFoundation for Polish Sciencees_ES
dc.date.accessioned2023-08-25T13:39:46Z
dc.date.available2023-08-25T13:39:46Z
dc.date.issued2023-07-12
dc.description.abstractNon-alcoholic fatty liver disease (NAFLD) is a type of steatosis commonly associated with obesity, dyslipidemia, hypertension, and diabetes. Other diseases such as inherited alpha-1 antitrypsin deficiency (AATD) have also been related to the development of liver steatosis. The primary reasons leading to hepatic lipid deposits can be genetic and epigenetic, and the outcomes range from benign steatosis to liver failure, as well as to extrahepatic diseases. Progressive hepatocellular damage and dysregulated systemic immune responses can affect extrahepatic organs, specifically the heart and lungs. In this review, we discuss the similarities and differences between the molecular pathways of NAFLD and AATD, and the putative value of hepatic organoids as novel models to investigate the physio pathological mechanisms of liver steatosis.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was supported by grants from Instituto de Salud Carlos III (ISCIII): AESI PI20CIII/00015 and PISCIIIBB-PT20CIII/00009, and by Polish National Science Centre Grants 2015/17/B/NZ5/01370 and 2018/29/B/NZ5/02346.es_ES
dc.format.number7es_ES
dc.format.page1961es_ES
dc.format.volume11es_ES
dc.identifier.citationBiomedicines. 2023 Jul 12;11(7):1961.es_ES
dc.identifier.doi10.3390/biomedicines11071961es_ES
dc.identifier.issn2227-9059es_ES
dc.identifier.journalBiomedicineses_ES
dc.identifier.pubmedID37509601es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16350
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/Subprograma Estatal de Generación de Conocimiento/PI20-ISCIII Modalidad Proyectos de Investigacion en Salud Intramurales. (2020)/PI20CIII/00015es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PISCIIIBB-PT20CIII/00009es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/biomedicines11071961es_ES
dc.repisalud.centroISCIII::Instituto de Investigación de Enfermedades Rarases_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAATDes_ES
dc.subjectNAFLDes_ES
dc.subjectCardiovascular diseasees_ES
dc.subjectLipidses_ES
dc.subjectMeta-inflammationes_ES
dc.titleNAFLD and AATD Are Two Diseases with Unbalanced Lipid Metabolism: Similarities and Differenceses_ES
dc.typereview articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication177cd6c3-16e8-4957-a3cc-98f752e549c5
relation.isAuthorOfPublication7f769ff1-83e3-45ed-a6d4-669418a419da
relation.isAuthorOfPublicationd0ee7849-1683-4c6e-b977-2a93cf579641
relation.isAuthorOfPublication1ddea53d-8bbc-4196-82a6-1f6b8ea3a92b
relation.isAuthorOfPublication.latestForDiscovery177cd6c3-16e8-4957-a3cc-98f752e549c5

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
NAFLD_AATD_AreTwoDiseases_2023.pdf
Size:
672.87 KB
Format:
Adobe Portable Document Format
Description: